Anixa Biosciences Cchek Prostate Cancer Confirmation Test

Anixa Biosciences launched its Cchek Prostate Cancer Confirmation test, which leverages the firm's AI- and flow cytometry-based liquid biopsy platform. The Cchek PCC test will be offered as a CLIA-validated test through Anixa's partner laboratory, ResearchDx, which validated it. The test, which uses a blood draw, is meant to confirm the need for prostate biopsy by measuring a patient's immunological response to malignancy by analyzing immune system cells in peripheral blood.